Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,547 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
Eyre TA, Preston G, Kagdi H, Islam A, Nicholson T, Smith HW, Cursley AP, Ramroth H, Xing G, Gu L, Rajakumaraswamy N, Fegan C. Eyre TA, et al. Among authors: xing g. Br J Haematol. 2021 Jul;194(1):69-77. doi: 10.1111/bjh.17475. Epub 2021 Jun 14. Br J Haematol. 2021. PMID: 34121184 Free PMC article.
Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Jones JA, et al. Among authors: xing g. Lancet Haematol. 2017 Mar;4(3):e114-e126. doi: 10.1016/S2352-3026(17)30019-4. Lancet Haematol. 2017. PMID: 28257752 Clinical Trial.
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, Kay NE, Shanafelt TD, Rabe KG, Byrd JC, Chanan-Khan AA, Furman RR, Hillmen P, Jones J, Seymour JF, Sharman JP, Ferrante L, Mobasher M, Stark T, Reddy V, Dreiling LK, Bhargava P, Howes A, James DF, Zelenetz AD. Soumerai JD, et al. Among authors: xing g. Lancet Haematol. 2019 Jul;6(7):e366-e374. doi: 10.1016/S2352-3026(19)30085-7. Epub 2019 May 17. Lancet Haematol. 2019. PMID: 31109827 Free PMC article.
Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N, Kinoshita T, Yamamoto K, Nagai H, Izutsu K, Yamamoto G, Bhargava P, Rajakumaraswamy N, Humeniuk R, Mathias A, Xing G, Fukui M, Tobinai K. Fukuhara N, et al. Among authors: xing g. Jpn J Clin Oncol. 2020 Dec 16;50(12):1395-1402. doi: 10.1093/jjco/hyaa153. Jpn J Clin Oncol. 2020. PMID: 32856068 Clinical Trial.
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas.
Wagner-Johnston ND, Schuster SJ, deVos S, Salles G, Jurczak WJ, Flowers CR, Viardot A, Flinn IW, Martin P, Xing G, Rajakumaraswamy N, Gopal AK. Wagner-Johnston ND, et al. Among authors: xing g. Leuk Lymphoma. 2021 May;62(5):1077-1087. doi: 10.1080/10428194.2020.1855344. Epub 2020 Dec 10. Leuk Lymphoma. 2021. PMID: 33300385 Clinical Trial.
Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Ma S, Chan RJ, Gu L, Xing G, Rajakumaraswamy N, Ruzicka BB, Wagner-Johnston ND. Ma S, et al. Among authors: xing g. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):e432-e448. doi: 10.1016/j.clml.2020.12.016. Epub 2020 Dec 24. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33516721 Free article.
Idelalisib immune-related toxicity is associated with improved treatment response.
Wagner-Johnston ND, Sharman J, Furman RR, Salles G, Brown JR, Robak T, Gu L, Xing G, Chan RJ, Rajakumaraswamy N, Gopal AK. Wagner-Johnston ND, et al. Among authors: xing g. Leuk Lymphoma. 2021 Dec;62(12):2915-2920. doi: 10.1080/10428194.2021.1948038. Epub 2021 Jul 28. Leuk Lymphoma. 2021. PMID: 34319205 Free PMC article.
1,547 results